Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15B | O15296 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835066 | 0.94 | ALOX15B (0.56) | ALOX15BALOX12ALDH1A1HPGDALOX5 | |
| SCHEMBL4839493 | 0.92 | ALOX15B (0.57) | ALOX15BALOX12ALDH1A1HPGDALOX5 | |
| SCHEMBL4841458 | 0.77 | MAPT (0.55) | ALDH1A1HPGDMEN1LMNAKMT2A | |
| SCHEMBL14017469 | 0.74 | ALOX5 (0.68) | ALOX15BALOX12ALOX5 | |
| SCHEMBL5103553 | 0.73 | ALOX5 (0.59) | ALOX15BALOX12ALOX5 | |
| SCHEMBL14195920 | 0.72 | MAPT (0.51) | ALDH1A1HPGDMEN1LMNAHTT | |
| SCHEMBL14288241 | 0.71 | ALOX15B (0.69) | ALOX15BALOX12ALOX5 | |
| SCHEMBL14017472 | 0.71 | ALOX5 (0.69) | ALOX15BALOX5 | |
| SCHEMBL4836675 | 0.71 | ALDH1A1 (0.58) | ALDH1A1HPGDMEN1LMNAHTT | |
| SCHEMBL14017476 | 0.71 | ALOX5 (0.63) | ALOX15BALOX12ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351727-B2 | Inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351727-B2 | Inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351727-B2 | Inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-20050065198-A1 | Inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065198-A1 | Inhibitors of 15-lipoxygenase | ALOX15, ALOX5, ALOX15B | ALOX15B 3/4885ALOX12 4/4885ALDH1A1 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.